BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 2015;165:306-20. [PMID: 25468487 DOI: 10.1016/j.trsl.2014.10.010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Botzanowski T, Hernandez-alba O, Malissard M, Wagner-rousset E, Deslignière E, Colas O, Haeuw J, Beck A, Cianférani S. Middle Level IM–MS and CIU Experiments for Improved Therapeutic Immunoglobulin Subclass Fingerprinting. Anal Chem 2020;92:8827-35. [DOI: 10.1021/acs.analchem.0c00293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Tiwari N, Upadhyay J, Ansari MN, Joshi R. Novel β-Coronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments. Saudi Pharm J 2020;28:1243-52. [PMID: 32868970 DOI: 10.1016/j.jsps.2020.08.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Condom P, Mansuy JM, Decramer S, Izopet J, Mengelle C. Atypical hemolytic uremic syndrome triggered by varicella infection. IDCases 2017;9:89-90. [PMID: 28725563 DOI: 10.1016/j.idcr.2017.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Pérez-Calatayud ÁA, Briones-Garduño JC, Álvarez-Goris Mdel P, Sánchez Zamora R, Torres Aguilar AA, Mendoza-Mórales RE. [Atipical uremic hemolityc syndrome in pregnancy]. Cir Cir 2016;84:344-9. [PMID: 27004941 DOI: 10.1016/j.circir.2016.02.001] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
6 Ling M, Murali M. Analysis of the Complement System in the Clinical Immunology Laboratory. Clin Lab Med 2019;39:579-90. [PMID: 31668271 DOI: 10.1016/j.cll.2019.07.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
7 Lau C, McAdam MB, Bergseth G, Grevys A, Bruun JA, Ludviksen JK, Fure H, Espevik T, Moen A, Andersen JT, Mollnes TE. NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies. MAbs 2020;12:1686319. [PMID: 31671278 DOI: 10.1080/19420862.2019.1686319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Conway EM. Thrombin: Coagulation's master regulator of innate immunity. J Thromb Haemost 2019;17:1785-9. [DOI: 10.1111/jth.14586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Morgan BP. The membrane attack complex as an inflammatory trigger. Immunobiology 2016;221:747-51. [PMID: 25956457 DOI: 10.1016/j.imbio.2015.04.006] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 12.9] [Reference Citation Analysis]
10 Souto EB, Lima B, Campos JR, Martins-Gomes C, Souto SB, Silva AM. Myasthenia gravis: State of the art and new therapeutic strategies. J Neuroimmunol 2019;337:577080. [PMID: 31670062 DOI: 10.1016/j.jneuroim.2019.577080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Brachet G, Bourquard T, Gallay N, Reiter E, Gouilleux-gruart V, Poupon A, Watier H. Eculizumab epitope on complement C5: Progress towards a better understanding of the mechanism of action. Molecular Immunology 2016;77:126-31. [DOI: 10.1016/j.molimm.2016.07.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
12 Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev 2021;3:CD012862. [PMID: 33783815 DOI: 10.1002/14651858.CD012862.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Michailidou I, Jongejan A, Vreijling JP, Georgakopoulou T, de Wissel MB, Wolterman RA, Ruizendaal P, Klar-Mohamad N, Grootemaat AE, Picavet DI, Kumar V, van Kooten C, Woodruff TM, Morgan BP, van der Wel NN, Ramaglia V, Fluiter K, Baas F. Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis. Acta Neuropathol Commun 2018;6:36. [PMID: 29724241 DOI: 10.1186/s40478-018-0536-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
14 Quintana LF, Kronbichler A, Blasco M, Zhao MH, Jayne D. ANCA associated vasculitis: The journey to complement-targeted therapies. Mol Immunol 2019;112:394-8. [PMID: 31291610 DOI: 10.1016/j.molimm.2019.06.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
15 Rondeau E, Cataland SR, Al-Dakkak I, Miller B, Webb NJA, Landau D. Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney Int Rep 2019;4:1568-76. [PMID: 31890998 DOI: 10.1016/j.ekir.2019.07.016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
16 Blom AM, Österborg A, Mollnes TE, Okroj M. Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Molecular Immunology 2015;66:164-70. [DOI: 10.1016/j.molimm.2015.02.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
17 Zilberman-Itskovich S, Abu-Hamad R, Stark M, Efrati S. Effect of anti-C5 antibody on recuperation from ischemia/reperfusion-induced acute kidney injury. Ren Fail 2019;41:967-75. [PMID: 31662004 DOI: 10.1080/0886022X.2019.1677248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Top O, Parsons J, Bohlender LL, Michelfelder S, Kopp P, Busch-Steenberg C, Hoernstein SNW, Zipfel PF, Häffner K, Reski R, Decker EL. Recombinant Production of MFHR1, A Novel Synthetic Multitarget Complement Inhibitor, in Moss Bioreactors. Front Plant Sci 2019;10:260. [PMID: 30949184 DOI: 10.3389/fpls.2019.00260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
19 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 20.6] [Reference Citation Analysis]
20 Barnum SR. Complement: A primer for the coming therapeutic revolution. Pharmacol Ther 2017;172:63-72. [PMID: 27914981 DOI: 10.1016/j.pharmthera.2016.11.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
21 Foley JH, Walton BL, Aleman MM, O'Byrne AM, Lei V, Harrasser M, Foley KA, Wolberg AS, Conway EM. Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin. EBioMedicine 2016;5:175-82. [PMID: 27077125 DOI: 10.1016/j.ebiom.2016.02.011] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 10.5] [Reference Citation Analysis]
22 So S, Fischer E, Gangadharan Komala M, Bose B. Postpartum atypical hemolytic uremic syndrome: Evaluating thrombotic microangiopathy in the pregnant woman. Obstet Med 2021;14:105-8. [PMID: 34394720 DOI: 10.1177/1753495X20926043] [Reference Citation Analysis]
23 Howard JF Jr. Myasthenia gravis: the role of complement at the neuromuscular junction. Ann N Y Acad Sci 2018;1412:113-28. [PMID: 29266249 DOI: 10.1111/nyas.13522] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
24 Wester Trejo MAC, Trouw LA, Bajema IM. The role of complement in antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Rheumatol 2019;31:3-8. [PMID: 30461541 DOI: 10.1097/BOR.0000000000000557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Willrich MA, Andreguetto BD, Sridharan M, Fervenza FC, Tostrud LJ, Ladwig PM, Rivard AM, Hetrick MD, Olson RN, Bryant SC, Snyder MR, Murray DL. The impact of eculizumab on routine complement assays. Journal of Immunological Methods 2018;460:63-71. [DOI: 10.1016/j.jim.2018.06.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
26 Ricklin D, Reis ES, Lambris JD. Complement in disease: a defence system turning offensive. Nat Rev Nephrol. 2016;12:383-401. [PMID: 27211870 DOI: 10.1038/nrneph.2016.70] [Cited by in Crossref: 248] [Cited by in F6Publishing: 246] [Article Influence: 41.3] [Reference Citation Analysis]
27 Sakuma Y, Nagai T, Yoshio T, Hirohata S. Differential activation mechanisms of serum C5a in lupus nephritis and neuropsychiatric systemic lupus erythematosus. Mod Rheumatol 2017;27:292-7. [PMID: 27319578 DOI: 10.1080/14397595.2016.1193965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
28 Parry J, Hwang J, Stahel CF, Henderson C, Nadeau J, Stacey S, Beauchamp K, Moore EE, Stahel PF. Soluble terminal complement activation fragment sC5b-9: a new serum biomarker for traumatic brain injury? Eur J Trauma Emerg Surg 2021;47:1491-7. [DOI: 10.1007/s00068-020-01407-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Fox DA. Current and future approaches to the treatment of immunologic diseases: new targets and new therapeutic agents. Transl Res 2015;165:251-4. [PMID: 25468483 DOI: 10.1016/j.trsl.2014.10.009] [Reference Citation Analysis]
30 Ladwig PM, Barnidge DR, Willrich MA. Quantification of the IgG2/4 kappa Monoclonal Therapeutic Eculizumab from Serum Using Isotype Specific Affinity Purification and Microflow LC-ESI-Q-TOF Mass Spectrometry. J Am Soc Mass Spectrom 2017;28:811-7. [DOI: 10.1007/s13361-016-1566-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
31 Zavala-Tecuapetla C, Cuellar-Herrera M, Luna-Munguia H. Insights into Potential Targets for Therapeutic Intervention in Epilepsy. Int J Mol Sci 2020;21:E8573. [PMID: 33202963 DOI: 10.3390/ijms21228573] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
32 Latuszek A, Liu Y, Olsen O, Foster R, Cao M, Lovric I, Yuan M, Liu N, Chen H, Zhang Q, Xiao H, Springer C, Ehrlich G, Kamat V, Rafique A, Hu Y, Krueger P, Huang T, Poueymirou W, Babb R, Rosconi MP, Retter MW, Chen G, Morton L, Zambrowicz B, Cao J, Romano C, Olson WC. Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One 2020;15:e0231892. [PMID: 32384086 DOI: 10.1371/journal.pone.0231892] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
33 Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol 2017;13:538-47. [DOI: 10.1038/nrrheum.2017.125] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 19.0] [Reference Citation Analysis]
34 Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018;40:49-64. [PMID: 29327071 DOI: 10.1007/s00281-017-0663-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
35 Nguyen VP, Kobashigawa JA. Antibody-medicated rejection after heart transplantation: diagnosis and clinical implications. Curr Opin Organ Transplant 2020;25:248-54. [PMID: 32304428 DOI: 10.1097/MOT.0000000000000754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Ward PA, Fattahi F. New strategies for treatment of infectious sepsis. J Leukoc Biol 2019;106:187-92. [PMID: 30821872 DOI: 10.1002/JLB.4MIR1118-425R] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
37 Yatime L, Merle NS, Hansen AG, Friis NA, Østergaard JA, Bjerre M, Roumenina LT, Thiel S, Kristensen P, Andersen GR. A Single-Domain Antibody Targeting Complement Component C5 Acts as a Selective Inhibitor of the Terminal Pathway of the Complement System and Thus Functionally Mimicks the C-Terminal Domain of the Staphylococcus aureus SSL7 Protein. Front Immunol 2018;9:2822. [PMID: 30555486 DOI: 10.3389/fimmu.2018.02822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Badri P, Jiang X, Borodovsky A, Najafian N, Kim J, Clausen VA, Goel V, Habtemariam B, Robbie GJ. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet 2021;60:365-78. [PMID: 33047216 DOI: 10.1007/s40262-020-00940-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Giglhuber K, Berthele A. Eculizumab in the treatment of neuromyelitis optica spectrum disorder. Immunotherapy 2020;12:1053-66. [PMID: 32772617 DOI: 10.2217/imt-2020-0163] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Davis BP, Ballas ZK. Biologic response modifiers: Indications, implications, and insights. J Allergy Clin Immunol 2017;139:1445-56. [PMID: 28263774 DOI: 10.1016/j.jaci.2017.02.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
41 Matsuda Y, Sarwal MM. Unraveling the Role of Allo-Antibodies and Transplant Injury. Front Immunol 2016;7:432. [PMID: 27818660 DOI: 10.3389/fimmu.2016.00432] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
42 Makishima K, Obara N, Ishitsuka K, Sukegawa S, Suma S, Kiyoki Y, Baba N, Sakamoto T, Kato T, Kusakabe M, Nishikii H, Kurita N, Yokoyama Y, Sakata-Yanagimoto M, Hasegawa Y, Chiba S. High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease. Ann Hematol 2019;98:1031-2. [PMID: 30324459 DOI: 10.1007/s00277-018-3521-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
43 Henrickson SE, Ruffner MA, Kwan M. Unintended Immunological Consequences of Biologic Therapy. Curr Allergy Asthma Rep 2016;16:46. [PMID: 27324478 DOI: 10.1007/s11882-016-0624-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
44 Nagarajah S, Tepel M, Nielsen C, Assing K, Palarasah Y, Andersen LLT, Lange LB, Bistrup C. Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report. BMC Nephrol 2019;20:307. [PMID: 31390992 DOI: 10.1186/s12882-019-1469-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
45 Kobylarek D, Iwanowski P, Lewandowska Z, Limphaibool N, Szafranek S, Labrzycka A, Kozubski W. Advances in the Potential Biomarkers of Epilepsy. Front Neurol 2019;10:685. [PMID: 31312171 DOI: 10.3389/fneur.2019.00685] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
46 van Beers JJBC, Damoiseaux JGMC. Treatment of Autoimmune Diseases with Therapeutic Antibodies: Lessons Learned from PID Patients Allow for Stratification of the Infection Risk. Methods Mol Biol 2022;2313:27-44. [PMID: 34478130 DOI: 10.1007/978-1-0716-1450-1_2] [Reference Citation Analysis]
47 Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D; 311 Study Group Members. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. Kidney Int Rep 2021;6:1603-13. [PMID: 34169200 DOI: 10.1016/j.ekir.2021.03.884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]